Search Results
Your search for The A matches 32997 pages
Showing 23051 - 23100Amplification of 9p24.1 Associated With Advanced Stage and Poorer Outcome in Classic Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Roemer et al identified PD-L1 (programmed cell death ligand 1) and PD-L2 genetic alterations in patients with classic Hodgkin lymphoma, finding that 9p24.1 amplification was common and associated with advanced-stage disease and poorer...
Advantage of Afatinib vs Gefitinib in First-Line Treatment of EGFR-Mutant NSCLC
The irreversible ErbB family inhibitor afatinib (Gilotrif) was associated with improvement in progression-free survival and time to treatment failure vs the reversible EGFR (epidermal growth factor receptor) inhibitor gefitinib (Iressa) in the first-line treatment of EGFR-mutant non–small...
Natural Cancer Remedies
The cost and side effects associated with traditional cancer therapy are major concerns, and in part many patients are seeking natural remedies such as graviola, curcumin, and moringa, due to these concerns. Traditional cancer therapy is increasingly effective, and oncologists are achieving better...
Blue Ribbon Panel to Help Guide Cancer Moonshot Initiative
As described in the full report on page 39, the National Cancer Institute (NCI) announced a Blue Ribbon Panel of experts and advocates who will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer Moonshot Initiative. Members of the research community and...
Severe Adverse Event Clusters Identified Using NCI Common Terminology Criteria
Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), researchers from Columbia University, New York, and Fred Hutchinson Cancer Research Center, Seattle, identified six severe adverse event clusters in patients with advanced prostate cancer. The clusters...
Earlier Hospice Enrollment, Avoiding ICU Admissions, and Not Dying in the Hospital Associated With Perceptions of Better End-of-Life Care
Three measures of aggressive end-of-life care “were associated with relatively large differences in family member–reported quality ratings for end-of-life care and a lower likelihood that patients with advanced-stage cancer received care congruent with their preferences,” according to a study in...
High-Accuracy Metabolomic Detection of Early-Stage Ovarian Cancer
As reported in Scientific Reports, Gaul and colleagues used high-performance mass spectrometry to interrogate the serum metabolome of patients with early-stage ovarian cancer and healthy controls. They were able to define a linear support vector machine model of 16 metabolites that identified...
Choline Kinase Alpha as Androgen Receptor Chaperone and Prostate Cancer Target
As reported in the Journal of the National Cancer Institute, Asim and colleagues found that choline kinase alpha (CHKA) acts as a chaperone for the androgen receptor (AR) and may serve as a therapeutic target in prostate cancer. CHKA expression was found to be androgen regulated in cell lines,...
Potential Role for HSP70 Peptide Aptamer in Restoring Anticancer Immune Response
Exosomes can activate myeloid-derived suppressor cells via interaction of membrane heat shock protein 70 (HSP70) with Toll-like receptor 2 (TLR2) on the myeloid-derived suppressor cell. As reported in the Journal of the National Cancer Institute, Gobbo and colleagues found that the A8 peptide...
PTK2/FAK as Driver of Radioresistance in HPV-Negative Head and Neck Squamous Cell Carcinoma
As reported in Clinical Cancer Research, Skinner and colleagues used proteomic profiling to identify PTK2/FAK as a driver of radioresistance in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma. Using proteomic and transcriptomic analysis of targetable markers, the...
Potential Biomarker for Carfilzomib Activity in CLL
Carfilzomib (Kyprolis) is active in B-cell neoplasms but exhibits heterogeneous activity in chronic lymphocytic leukemia (CLL) samples. As reported in Clinical Cancer Research, Lamothe and colleagues examined the mechanism by which carfilzomib induces CLL cell death. In studies using CLL patient...
APSHO to Hold Skills Workshops for Advanced Practitioners in Oncology
The Advanced Practitioner Society for Hematology and Oncology (APSHPO) has announced a series of workshops to be held in cities nationwide during 2016. APSHO, a nonprofit membership organization consisting of nurse practitioners, physician assistants, pharmacists, clinical nurse specialists, and...
Expect Questions About Potential Trade-Offs of Contralateral Prophylactic Mastectomy
Women who were diagnosed with breast cancer and had contralateral prophylactic mastectomy had only marginal improvement in psychosocial well-being, such as feeling confident and emotionally healthy, according to a study published in the Journal of Clinical Oncology.1 Those who also had breast...
Quality-of-Life Benefits of Contralateral Prophylactic Mastectomy May Be Too Small to Be Clinically Meaningful
Women diagnosed with breast cancer who chose contralateral prophylactic mastectomy reported improvement in psychosocial well-being and breast satisfaction, but “the magnitude of the effect may be too small to be clinically meaningful,” according to a study in the Journal of Clinical Oncology.1...
City of Hope Awarded $2.5 Million Grant to Launch Nutrition Initiative
Funded by a $2.5 million grant from the Conrad N. Hilton Foundation, City of Hope has launched a 5-year initiative to reduce cancer risk in the Los Angeles area by promoting healthy eating and physical activity, particularly among school children. The long-range plan is to replicate the...
Director Selected for NIH’s Precision Medicine Initiative Cohort Program
Francis S. Collins, MD, PhD, Director, National Institutes of Health (NIH), recently released the statement below: I am very pleased to announce the selection of Eric Dishman as Director of the Precision Medicine Initiative (PMI) Cohort Program. Eric will lead NIH’s effort to build the PMI...
Ed Sauter, MD, PhD, Named Director of Breast Surgery Program at Hartford HealthCare Cancer Institute
Hartford HealthCare Cancer Institute announced the appointment of Ed Sauter, MD, PhD, as Director of the Breast Surgery Program at the Hartford HealthCare Cancer Institute (HHCCI). He will lead the breast surgery programs at each of the Institute’s five cancer centers. Dr. Sauter is joining the...
Friends of Cancer Research Encourages FDA to Modernize and Consolidate
“In order to take advantage of today’s advancements in science, drug development, and patient treatment, the U.S. Food and Drug Administration’s (FDA’s) structure needs reorganization to focus its resources and ensure the best outcomes for patients. Friends of Cancer Research (Friends) proposes...
Larry W. Kwak, MD, PhD, Awarded Ho-Am Prize in Medicine
Physician and scientist Larry W. Kwak, MD, PhD, Director of City of Hope’s Toni Stephenson Lymphoma Center, has been awarded the 2016 Ho-Am Prize in Medicine, which recognizes people of Korean heritage who have made impressive contributions in clinical and research areas that contributed to the...
Raising Awareness of Medullary Thyroid Carcinoma
I’m used to having bumps and cysts pop up on my body, so when I felt a lump on the front of my throat, just below my Adam’s apple, I brushed it off. But when it was still there 6 months later, I became concerned and decided to see an ear, nose, and throat specialist. He performed a fine-needle...
2016–2017 HOPA President Sarah Scarpace, PharmD, MPH, BCOP, Takes Office
The Hematology/Oncology Pharmacy Association (HOPA) has elected Sarah Scarpace, PharmD, MPH, BCOP, to serve as President for the 2016–2017 term. Dr. Scarpace recently took office at the 12th HOPA Annual Conference, held March 16–19 in Atlanta, Georgia. Dr. Scarpace has served as President-Elect...
Susannah Koontz, PharmD, BCOP, FHOPA, Named HOPA President-Elect for 2016–2017 Term
Susannah Koontz, PharmD, BCOP, FHOPA, took office as President-Elect of the Hematology/Oncology Pharmacy Association (HOPA) at the recent 12th HOPA Annual Conference, held March 16–19 in Atlanta, Georgia. Dr. Koontz will serve as President-Elect for the 2016–2017 term and assume the office of...
Radiation: Myths, Facts, Dangers and Benefits
For many, the word “radiation” conjures up images of mushroom clouds and the nightmarish nuclear disaster at Chernobyl. It also brings to mind those pesky dental x-rays and lifesaving cancer treatments. However, to most people, radiation is a mysterious invisible power to be feared and embraced...
Immunotherapy Could Be the Wave of the Future, but Problems and Challenges Cannot Be Ignored
Immunotherapy is on its way. A few agents have already been approved: ipilimumab (Yervoy) in 2011 for melanoma; nivolumab (Opdivo) in 2015 for non–small cell lung cancer (NSCLC) and then later that year for renal cell carcinoma; and pembrolizumab (Keytruda) for NSCLC. In addition, many clinical...
Supportive Care in the Older Adult With Cancer: What You Need to Know
The median age of patients at the first diagnosis of cancer in the United States is 65 years, and the majority of patients with cancer are older adults.1 As we have learned from previous articles in this series, older patients with cancer require more complex care. Older adults are more likely to...
ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent Cancer
Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young people in the United States—and millions worldwide—from life-threatening cancers, ASCO said April 11 in a policy statement. Published by Bailey et al in the Journal of Clinical Oncology,1 the...
Praise for the ACS/ASCO Breast Cancer Survivorship Care Guideline
The recent publication of the American Cancer Society (ACS)/ASCO breast cancer survivorship care guideline is a tremendous contribution to the literature and should provide a roadmap for providers who care for patients with a history of breast cancer for years to come.1,2 The guideline, reported by ...
ACS/ASCO Breast Cancer Survivorship Care Guideline
The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians.1,2 The guideline recommendations were formulated by a multidisciplinary expert work group and are based...
Leena Gandhi, MD, PhD, Named Director of Thoracic Medical Oncology at NYU Langone’s Perlmutter Cancer Center
New York University (NYU) Langone Medical Center has announced the appointment of physician-scientist Leena Gandhi, MD, PhD, as Director of Thoracic Medical Oncology at its Laura and Isaac Perlmutter Cancer Center. In this new role, Dr. Gandhi will be tasked with building a robust program in lung...
Johns Hopkins Launches Immunotherapy Center With $125 Million Gift
A new institute studying immunology was announced on March 29 at Johns Hopkins by Vice President Joe Biden, Michael R. Bloomberg, and more than a dozen additional supporters of this initiative. Embracing the Vice President’s “moonshot” initiative to cure cancer, the new Bloomberg–Kimmel Institute...
Drug Prices and Value: Finding Middle Ground
The advent of targeted therapies along with complex personalized treatment regimens has added many effective tools to the oncology armamentarium. But progress has a price tag. Although the oncology community needs new drugs, there is growing concern that the price of many newer compounds is...
Podcast Discusses Finding Easy-to-Understand Cancer Information
It’s easy for patients to find information about cancer on the Internet, but finding information that is both accurate and understandable may not be so easy. Cancer.Net’s Editor-in-Chief Lidia Schapira, MD, FASCO, recently joined Fergal McGovern on Empowered Patient Radio to discuss the challenges...
ASCO Convenes Obesity Work Group Meeting on Multidisciplinary Collaboration
ASCO recently held a work group meeting with 18 organizations that focused on addressing obesity through multidisciplinary collaboration. The purpose of the meeting was to review current challenges in addressing obesity within the health-care provider communities and identify potential...
2016 Special Awards: Researchers and Scientists Recognized for Significant Contributions to Cancer Care
Researchers, patient advocates, and global oncology community leaders dedicated to enhancing cancer prevention, treatment, and patient care will be honored with ASCO’s highest honor, its Special Awards, during the 2016 ASCO Annual Meeting. Among this year’s awardees are a lung cancer luminary who...
Meet W. Charles Penley, MD, FASCO
A Partner at Tennessee Oncology, PLLC, W. Charles Penley, MD, FASCO, has been an ASCO member since 1988. He has served on the Conquer Cancer Foundation Board of Directors since 2005 and currently holds the role of Immediate Past Chair. What led you to oncology? WCP: While it may sound silly to say ...
AACR 2016: Genomic Variants May Influence Risk for Breast Cancer After Chest Radiotherapy to Treat Childhood Cancer
Among females who received radiotherapy to the chest as part of treatment for a childhood cancer, those who had either of two specific genetic variants were at significantly higher risk of developing breast cancer later in life, according to research presented by Morton et al at the 2016 AACR...
AACR 2016: Cologuard Detected Colorectal Cancer in Previously Unscreened Patients
A noninvasive colorectal cancer-screening test detected the disease in patients who had previously avoided more invasive screening measures, according to research presented by Prince et al at the 2016 AACR Annual Meeting (Abstract LB-296). The study of nearly 400 patients revealed four patients...
KIR3DL1 and HLA-B Allele Combinations May Impact Response to Treatment in Neuroblastoma
In a study reported in the Journal of Clinical Oncology, Forlenza et al found that noninteracting KIR3DL1 and HLA-B subtypes were associated with better response to anti-GD2 antibody treatment in neuroblastoma. Study Details Treatment of neuroblastoma with anti-GD2 monoclonal antibody (eg, the...
AACR 2016: Nivolumab Improved Survival for Patients With Head and Neck Squamous Cell Carcinoma
For the latest information on CheckMate-141, click here, here, or here. Treatment with the immunotherapeutic nivolumab (Opdivo) improved survival for patients with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy compared with...
Adjuvant Trastuzumab May Be Insufficiently Used in Older Women With Breast Cancer
Reeder-Hayes et al found that adjuvant trastuzumab (Herceptin) may be underused in older women with early-stage HER2-positive breast cancer and reported their study results in the Journal of Clinical Oncology. Adjuvant trastuzumab also was used less often in black women than in white women. Rates...
Adding Rituximab to Dose-Dense Chemotherapy May Be of Benefit in Burkitt Lymphoma
In a French phase III trial reported in The Lancet, Ribrag et al showed that adding rituximab (Rituxan) to dose-dense chemotherapy improved event-free survival among adults with Burkitt lymphoma. Study Details In the open-label trial, 260 patients were randomized between October 2004 and...
Boswellia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. We chose Boswellia for this issue because of its increasing use by patients with cancer....
Blue Ribbon Panel to Help Guide National Cancer Moonshot Initiative
On April 4, 2016, The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer ...
Scott A. Armstrong, MD, PhD, to Lead Department of Pediatric Oncology at Dana-Farber Cancer Institute
Scott A. Armstrong, MD, PhD, has been named Chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute and the David G. Nathan Professor of Pediatrics at Dana-Farber Cancer Institute, Boston Children’s Hospital, and Harvard Medical School. He will also serve as Associate Chief of ...
Expert Point of View: Thierry Facon, MD
Thierry Facon, MD, of Lille University Hospital in France, told The ASCO Post that he believes elotuzumab (Empliciti) works better with an immunomodulatory drug than with bortezomib (Velcade), at least according to the results of these two studies. “I think what’s most impressive is the ELOQUENT-2 ...
Updates on Elotuzumab in Multiple Myeloma Show Persistence of Benefit
Studies presented at the 2015 ASH Annual Meeting bolstered support for elotuzumab (Empliciti) given in combination with lenalidomide (Revlimid) for the treatment of multiple myeloma. Elotuzumab is an immunostimulatory monoclonal antibody. It has a dual mechanism of action, directly activating...
Expert Point of View: Thierry Facon, MD
Thierry Facon, MD, of Lille University Hospital in France, spoke to The ASCO Post about the preliminary results of the pembrolizumab studies. Dr. Facon cautioned that a response rate of 76% overall “is not so impressive,” given about 65% of patients respond to lenalidomide/dexamethasone alone....
Pembrolizumab Looks Promising in Multiple Myeloma
Monoclonal antibodies targeting the programmed cell death protein (PD-1) receptor look promising in multiple myeloma, according to early reports presented at the 2015 ASH Annual Meeting and Exposition. Early signs of activity in heavily pretreated patients may indicate that, as in solid tumors,...
Active Surveillance Has Become Standard Care for Men With Low-Risk Localized Prostate Cancer
Active surveillance has been increasingly adopted as a standard approach for men with Gleason score ≤ 6 localized prostate cancer, with major guidelines and consensus statements encouraging this approach,1 including a recently published guideline from Cancer Care Ontario (CCO),2 and endorsement of...
DigniCap Scalp-Cooling System Now Available for Women With Breast Cancer at 10 U.S. Cancer Treatment Centers
Dignitana Inc. recently announced that the DigniCap scalp cooling system, which was cleared by the U.S. Food and Drug Administration (FDA) in December 2015 to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now available at 10 cancer treatment...
